Receive The Newest Study Notifications

GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

IND Application Submitted to FDA for Phase 1 Trial ATLANTA, GA, Oct. 24, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX) announced today its participation in a planned clinical trial led by researchers at American Gene Technologies...

Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors...

Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle...

Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDPatients in the Third Cohort of OPTIC will Receive a Single ADVM-022 Dose of 2 x 10 ^11 vg/eye

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

MENLO PARK, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc., (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the third...

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical...

Segal Trials Acquires New Studies with Schedule 1 DEA License and Continues to Expand its Network of Inpatient and Outpatient Facilities

by Lance Smith | Oct 23, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Segal Trials, a privately held network of research sites throughout South Florida and South Carolina conducting Phase I–IV trials, has been named one of seven sites to begin a Phase II study of psilocybin—a psychedelic prodrug compound—for major depressive disorder...